HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica.

AuthorsGerhard Kolde, J Marcus Muche, Peter Schulze, Peter Fischer, Jürgen Lichey
JournalDermatology (Basel, Switzerland) (Dermatology) Vol. 206 Issue 2 Pg. 180-1 ( 2003) ISSN: 1018-8665 [Print] Switzerland
PMID12592093 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Adult
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Dermatologic Agents (adverse effects, therapeutic use)
  • Humans
  • Infliximab
  • Leg Ulcer (pathology)
  • Male
  • Necrobiosis Lipoidica (drug therapy, pathology)
  • Tumor Necrosis Factor-alpha (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: